AkrivisBio
Private Company
Total funding raised: $50M
Overview
AkrivisBio is a private, early-revenue biotechnology tools company that develops and sells biochemical assays and research reagents. Its core value proposition is offering assays that are easier to use, more sensitive, and less expensive than competitors', targeting foundational research in oncology, immunology, neuroscience, and metabolic diseases. The company leverages a team with deep academic and industrial experience in assay development and maintains a distributor-based sales model. While not a therapeutic developer, AkrivisBio positions itself as an enabler of drug discovery and basic research through its product portfolio.
Technology Platform
Portfolio of biochemical and enzyme activity assays designed for high sensitivity, precision, reproducibility, ease of use, and lower cost.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
AkrivisBio competes in the crowded life science reagents and assays market against giants like Abcam, BioVision, Cayman Chemical, and MilliporeSigma. Its differentiation is based on claiming superior precision, ease of use, and lower cost for its portfolio of biochemical and enzymatic assays.